TSC22D4-C7orf61 readthrough fusion protein

TSC22D4-C7orf61 readthrough is a naturally occurring *readthrough transcript* produced from the adjacent TSC22D4 and C7orf61 genes on chromosome 7. It encodes a fusion protein that combines sequence from both individual gene products. The specific biological function is not established. Both component genes are protein-coding: TSC22D4 is a leucine zipper transcriptional repressor involved in systemic glucose homeostasis and possibly neuronal processes, while the C7orf61 gene is of unknown function. Importantly, the readthrough transcript and its protein product have not been established as therapeutic targets, and no canonical abbreviation or common usage exists for this fusion. Increased expression of TSC22D4 and C7orf61, individually, has been reported in Alzheimer's disease brain tissue, suggesting potential but uncharacterized disease relevance. However, the fusion product itself lacks functional annotation, known molecular interactions, or therapeutic context, and does not conform to drug target conventions[1][3]. **Note:** - This entry appears to be computationally defined from genome annotation, not a well-characterized, canonical therapeutic target; it should not be treated as such without further validation. - Structured information for TSC22D4 (TSC22 domain family member 4) alone is available, but the *readthrough fusion* is not a standard biomedical target[1][5].

Other names

TSC22D4-C7orf61TSC22D4-C7ORF61 readthroughC7orf61-TSC22D4 fusion protein